TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19335751
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at a dosage of 90 microg kg(‐1) repeated every 3 h if needed
Study: 19335751
Drug: Activated prothrombin
Normalized name: Activated prothrombin complex concentrate
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated prothrombin complex concentrate (aPCC) at a dosage of 75 IU kg(‐1) repeated every 12 h if needed
Study: 11560814
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus caffeine
Study: 3350031
Drug: Intervention not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention not specified in the abstract, but involved antihypertensive regimens.
Study: 9422292
Drug: droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 1.25 mg
Study: 23955482
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg Se/day as high‐Se yeast
Study: 17890759
Drug: Cognitive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive lifestyle program focusing on weight loss, diet, and exercise; details on dosage and duration not specified.
Study: 17890759
Drug: Usual care;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care; details on dosage and duration not specified.
Study: 17890759
Drug: Cognitive lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive lifestyle program; details on dosage and duration not specified.
Study: 12473989
Drug: Long-term protocol
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term protocol (LTP) - 60 micro g PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no treatment for 40 weeks.
Study: 12473989
Drug: Short-term protocol
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term protocol (STP) - 60 micro g PGE1 twice a day for 2 days, repeated every 4 weeks.
Study: 10520386
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg (group T)
Study: 15518095
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (group O)
Study: 8643964
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m2) and Doxorubicin (60 mg/m2) administered in alternating schedules (3-hour infusion for paclitaxel and intravenous bolus for doxorubicin)
Study: 8643964
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) and Doxorubicin (60 mg/m2) administered with a 30-minute doxorubicin infusion preceding a 3-hour paclitaxel infusion every 3 weeks
Study: 8643964
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose levels of paclitaxel/doxorubicin (175 mg/m2 and 60 mg/m2)
Study: 2343728
Drug: Methohexital 2
Normalized name: methohexital 2.5 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital 2 mg/kg
Study: 7390377
Drug: Bromopride (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromopride (one capsule three times daily for three weeks)
Study: 7390377
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule three times daily for three weeks)
Study: 28266082
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of EGCG daily until full term
Study: 23641215
Drug: GSK1440115 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1440115 (750 mg)
Study: 21434335
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (DHI) combined with conventional therapy
Study: 11334133
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) such as beclomethasone, budesonide, and fluticasone
Study: 10969345
Drug: Persons with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persons with a history of injection drug use (HIV-1 RNA levels)
Study: 3922903
Drug: TTS 10
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTS 10 (10 mg nitroglycerin over 24 hours)
Study: 3922903
Drug: ISDN (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (20 mg slow-release)
Study: 30468108
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use prior to imprisonment; Alcohol (73%), Cigarettes (71%), Illicit drug use (27%), Injectable drug use (11%)
Study: 27126398
Drug: Sertraline, venlafaxine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, venlafaxine, nefazodone
Study: 27126398
Drug: Paroxetine, fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine, fluoxetine
Study: 27126398
Drug: Aripiprazole, divalproex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole, divalproex, guanfacine, olanzapine (combined with an antidepressant)
Study: 24816151
Drug: Standard vest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vest plus retroreflective strips positioned on the extremities in a configuration that conveyed biological motion (biomotion)
Study: 23093479
Drug: Ketorolac/hyoscine butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac/hyoscine butylbromide (10 mg/20 mg)
Study: 23093479
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (20 mg)
Study: 20485915
Drug: Non-oily capsules
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-oily capsules containing vitamin D3 66,000 UI plus vitamin A 13,200 UI
Study: 18589718
Drug: ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5 mg two times a day)
Study: 7674186
Drug: Resin‐modified glass‐ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin‐modified glass‐ionomer cement with a dentinal bonding agent
Study: 31736022
Drug: Intraperitoneal levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal levobupivacaine 20 mL
Study: 31736022
Drug: Incisional levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional levobupivacaine 20 mL
Study: 31736022
Drug: Intraperitoneal +
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal + Incisional levobupivacaine 20 mL each
Study: 22767584
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 100 mg/m(2) for 14 consecutive days in six 28-day cycles (CMF)
Study: 22767584
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (CMF or AC, provider/patient choice)
Study: 19925626
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan (6 mg) with MAOI-A
Study: 18666395
Drug: Fluocinonide cream
Normalized name: Fluocinonide Cream
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide cream 0.1%
Study: 18666395
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream 0.05%
Study: 16424840
Drug: Less incision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less incision retroperitoneal approach (group-L), incision length 11.9±1.8 cm
Study: 11789185
Drug: Danzhi Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danzhi Xiaoyao powder (DZXY) with conventional therapy
Study: 9298051
Drug: 0.03% topical
Normalized name: Levatio 5%-0.03% Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% topical flurbiprofen
Study: 27366013
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 300 mg once daily for 12 weeks
Study: 18156665
Drug: Amino acid/creatine/energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid/creatine/energy supplement (S)
Study: 15889114
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (8 and 40 mU/m2/min)
Study: 9390112
Drug: Montelukast 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 50 mg
Study: 9390112
Drug: Montelukast 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 2 mg
Study: 9657560
Drug: Montelukast (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (pooled 10 and 50 mg)
Study: 12162473
Drug: Ibuprofen arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginate 200 mg
Study: 12162473
Drug: Ibuprofen arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginate 400 mg
Study: 12242597
Drug: Ibuprofen arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginate 200 mg and 400 mg
Study: 11554954
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg and 400 mg
Study: 6812301
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg diltiazem t.i.d.
Study: 6812301
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg diltiazem t.i.d. (after dose increase)
Study: 6812301
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine t.i.d.
Study: 6812301
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine t.i.d.
Study: 6812301
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with diltiazem (60 mg or 90 mg t.i.d.)
Study: 31290981
Drug: Hydrocortisone replacement
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone replacement therapy at doses of 10, 20, or 30 mg/d for 4 weeks per term for three terms
Study: 22658378
Drug: ixabepilone 40
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ixabepilone 40 mg/m² on day 1 plus capecitabine 1000 mg/m² BID on days 1 to 14
Study: 22658378
Drug: No/late dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: No/late dose reduction of ixabepilone
Study: 11432891
Drug: Cetuximab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (loading dose of 100 to 500 mg/m², followed by weekly infusions of 100 to 250 mg/m² for 7 to 8 weeks) + Radiation Therapy (RT) (70 Gy, 2 Gy/d or hyperfractionated RT 76.8 Gy, 1.2 Gy bid)
Study: 9537429
Drug: Lanreotide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (all doses)
Study: 7702357
Drug: Intravenous cibenzoline
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cibenzoline administered as a 2 minute bolus at a dose of 1.2 mg.kg‐1
Study: 7702357
Drug: Intravenous cibenzoline
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cibenzoline administered as a 10 minute infusion at a dose of 1.75 mg.kg‐1
Study: 2596434
Drug: 390 mg
Normalized name: kaolin 390 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 390 mg ferrous sulfate/d for 2 months
Study: 240780
Drug: Rimiterol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimiterol (0.5 mug/kg/min high dose)
Study: 240780
Drug: Salbutamol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.3 mug/kg/min high dose)
Study: 240780
Drug: Isoprenaline (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (0.05 mug/kg/min high dose)
Study: 240780
Drug: Equal bronchodilator
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal bronchodilator action
Study: 28586279
Drug: Alectinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib (600 mg twice daily)
Study: 21675275
Drug: Proxodolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol (120 mg)
Study: 2454360
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg)
Study: 16926835
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel (SMEOF#3) 160 mg + CsA 700 mg
Study: 16926835
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel (Taxol) 160 mg + CsA 700 mg
Study: 16926835
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel (Taxol) 160 mg
Study: 15228716
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/child)
Study: 15228716
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/child) + Praziquantel (20 mg/kg)
Study: 3203713
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of methyldopa
Study: 21752985
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reminder letter and self-sampling
Study: 17295569
Drug: Schema-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-focused therapy (SFT)
Study: 21854625
Drug: Esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1 mg/kg
Study: 21600104
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 µg/kg
Study: 10734431
Drug: Control (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline, 2 mL, i.m.)
Study: 989409
Drug: Sleep deprivation/chlorimipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep deprivation/chlorimipramine therapy
Study: 989409
Drug: Chlorimipramine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine therapy
Study: 11224758
Drug: SonoVue (0.003
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (0.003 to 0.12 mL/kg for healthy volunteers; 4 mL for COPD patients)
Study: 9767284
Drug: Low incremental
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low incremental dose regimen
Study: 9767284
Drug: High incremental
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High incremental dose regimen
Study: 2532583
Drug: Once-a-day sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day sustained release preparation of anhydrous theophylline
Study: 19012954
Drug: MRKAd5 HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 HIV-1 gag/pol/nef vaccine (n=1494)
Study: 11835021
Drug: Subgroup randomization
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup randomization to energy levels of 0, 1, 2, 3, or 4 steps above implant DFT++ for conversion testing
Study: 2328298
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg N-acetylcysteine (NAC)
Study: 2328298
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg N-acetylcysteine (NAC)
Study: 2328298
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg N-acetylcysteine (NAC) twice a day for 5 days
Study: 2328298
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg N-acetylcysteine (NAC)
Study: 29027274
Drug: Natural turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural turmeric matrix formulation (CNTMF), 500 mg dose
Study: 29027274
Drug: Curcumin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin with volatile oil formulation, 500 mg dose
Study: 29027274
Drug: Curcumin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin with phospholipids formulation, 500 mg dose
Study: 11094667
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of fentanyl 5 micrograms/ml in bupivacaine 0.2% with adrenaline 5 micrograms/ml at a rate of 2 ml/h for more than 48 hours
Study: 11094667
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of fentanyl 5 micrograms/ml in bupivacaine 0.2% without adrenaline at a rate of 2 ml/h for more than 48 hours
Study: 8218756
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ranitidine
Study: 8218756
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ranitidine
Study: 8218756
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ranitidine
Study: 8218756
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ranitidine
Study: 3304515
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha 10 mg intravesically
Study: 29998370
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg/day)
Study: 15699229
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1.5 g/d)
Study: 9728902
Drug: Befloxatone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone (10 mg)
Study: 7857357
Drug: Pidotimod (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (400 mg/day) for 60 days
Study: 2658674
Drug: Propofol (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (maintenance dose controlled to maintain light sleep levels C0 to D1)
Study: 2658674
Drug: Propofol (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (maintenance dose controlled to maintain deep sleep levels)
Study: 3518984
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg twice daily
Study: 6102487
Drug: Ketotifen 2
Normalized name: ketotifen 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2 mg twice daily
Study: 25231186
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg)
Study: 25785968
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg mongersen
Study: 25785968
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg mongersen
Study: 25785968
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mongersen
Study: 17542203
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide bleaching agent (Opalescence, OPA)
Study: 11699174
Drug: Placebo agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo agent (PLA)
Study: 15366527
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution (Periogard) mouth rinse
Study: 15366527
Drug: 0.05% cetylpyridinium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% cetylpyridinium chloride solution (Cepacol)
Study: 15366527
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution (Periogard)
Study: 9833852
Drug: HAART (zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, ritonavir 600 mg twice daily)
Study: 241192
Drug: Benzquinamide (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzquinamide (0.7 mg/kg)
Study: 29074303
Drug: dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine (1 μg kg−1, PLD)
Study: 29074303
Drug: dexmedetomidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine (2 μg kg−1, PHD)
Study: 26446165
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous bolus of methylprednisolone
Study: 17274922
Drug: Tamoxifen for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen for 2.5 years followed by aromatase inhibitor for 2.5 years
Study: 17274922
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of aromatase inhibitor
Study: 15265851
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menaquinone) 45 mg/d
Study: 15265851
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (symptomatic therapy for ascites and dietary advice)
Study: 791586
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg azapropazone daily for 2 weeks
Study: 791586
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg naproxen daily for 2 weeks
Study: 30847805
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®)
Study: 30847805
Drug: Repeat administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat administration of triamcinolone acetonide ER
Study: 30847805
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide crystalline suspension (CS)
Study: 19144173
Drug: Long-acting bronchodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting bronchodilators alone
Study: 19144173
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and combination treatment
Study: 17461719
Drug: lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir 400/100 mg twice-daily or 800/200 mg once-daily with gastric acid-reducing agents